

Clerk of the House of Representatives  
 Legislative Resource Center  
 B-106 Cannon Building  
 Washington, DC 20515

Secretary of the Senate  
 Office of Public Records  
 232 Hart Building  
 Washington, DC 20510

SECRETARY OF THE SENATE

00 AUG 14 AM 11:18

**LOBBYING REPORT**

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name Glaxo Wellcome, Inc.			
2. Address <input type="checkbox"/> Check if different than previously reported 1500 K Street, NW, Suite 650			
3. Principal Place of Business (if different from line 2) City: Washington, DC State/Zip (or Country) 20005			
4. Contact Name Janie A. Kinney	Telephone (202) 715-1000	E-mail (optional)	5. Senate ID # 16293-12
7. Client Name <input checked="" type="checkbox"/> Self	6. House ID # 31461000		

**TYPE OF REPORT** 8. Year 2000 Midyear (January 1-June 30)  OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report  ⇨ Termination Date \_\_\_\_\_ 11. No Lobbying Activity

**INCOME OR EXPENSES - Complete Either Line 12 OR Line 13**

<p><b>12. Lobbying Firms</b></p> <p><b>INCOME</b> relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇨ \$ _____  <small>Income (nearest \$20,000)</small></p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p><b>13. Organizations</b></p> <p><b>EXPENSES</b> relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇨ \$ <u>1,500,000</u>  <small>Expenses (nearest \$20,000)</small></p> <p><b>14. REPORTING METHOD.</b> Check box to indicate expense accounting method. See instructions for description of options.</p> <p><input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definitions only</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code</p>
---	--

Signature *Sarah J. Walsh*  
 Printed Name and Title Sarah J. Walsh, Director, Federal Government Relations

Registrant Name Glaxo Wellcome Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific lobbying issues

H.R. 1907 American Inventors Protection Act of 1999  
H.R. 434 Africa Growth & Opportunity Act  
S. 666 Africa Growth & Opportunity Act

17. House(s) of Congress and Federal agencies contacted  Check if None

US House of Representatives  
US Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	Net
Janie Kinney		<input type="checkbox"/>
Sara Froelich		<input type="checkbox"/>
Sarah J. Walsh		<input type="checkbox"/>
William Schuyler		<input type="checkbox"/>
Elizabeth Beavin		<input type="checkbox"/>
Kimberly A. Williams		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature  Date August 10, 2000

Printed Name and Title Sarah J. Walsh, Director, Federal Government Relations

Registrant Name Glaxo Wellcome Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

- S. 578 Health Care Personal Information Nondisclosure Act of 1999
- S. 881 Medical Information Protection Act of 1999
- H.R. 1057, S. 573 Medical Information Privacy & Security Act
- H.R. 2470 Medical Information Protection and Research Enhancement Act
- H.R. 1941 Health Information Privacy Act
- H.R. 216 Access to Quality Care Act
- H.R. 358, S. 6 Patients' Bill of Rights of 1999
- H.R. 4661, S. 1233 Agriculture Appropriations for 2001
- S. 2448 Medical Data Privacy


17. House(s) of Congress and Federal agencies contacted  Check if None

US House of Representatives  
US Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	Key
Janie Kinney		<input type="checkbox"/>
Sara Froelich		<input type="checkbox"/>
Sarah J. Walsh		<input type="checkbox"/>
William Schuyler		<input type="checkbox"/>
Elizabeth Beavin		<input type="checkbox"/>
Kimberly A. Williams		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature  Date August 10, 2000

Printed Name and Title Sarah J. Walsh, Director, Federal Government Relations

Registrant Name Glaxo Wellcome Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MED (one per page)

16. Specific lobbying issues

- S. 805 To provide asthma treatment services for children
- S. 1650, H.R. 3064 Appropriations for 2001 for Labor & HHS
- S. 2311, H.R. 4807 Ryan White Care Act Amendments of 2000
- H.R. 2840 Children's Asthma Relief Act of 1999
- H.R. 3301 Public Health Service Act
- H.R. 1965 For increased funding for asthma programs


17. House(s) of Congress and Federal agencies contacted  Check if None

US House of Representatives  
US Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	Yes
Janie Kinney		<input type="checkbox"/>
Sara Froelich		<input type="checkbox"/>
Sarah J. Walsh		<input type="checkbox"/>
William Schuyler		<input type="checkbox"/>
Elizabeth Beavin		<input type="checkbox"/>
Kimberly A. Williams		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature  Date August 10, 2000

Printed Name and Title Sarah J. Walsh, Director, Federal Government Relations

Registrant Name Glaxo Wellcome Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MM (one per page)

16. Specific lobbying issues

H.R. 664, S. 731 Prescription Drug Fairness for Seniors Act of 1999  
Medicare Drug Benefit Proposals  
H.R. 1090 The Medicare Full Access to Cancer Treatment Act  
S. 1895 Medicare Preservation & Improvement Act  
S. 1480, H.R. 2782 Seniors Prescription Insurance Coverage Equity Act  
H.R. 2012 Medicare Prescription Drug Benefit Act of 1999  
S. 841 Access to Rx Medications in Medicare  
S. 2836 Medicare Rx Drug Discount & Security Act of 2000  
H.R. 4680 Medicare Rx 2000 Act

17. House(s) of Congress and Federal agencies contacted  Check if None

US House of Representatives  
US Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Janie Kinney		<input type="checkbox"/>
Sara Froelich		<input type="checkbox"/>
Sarah J. Walsh		<input type="checkbox"/>
William Schuyler		<input type="checkbox"/>
Elizabeth Beavin		<input type="checkbox"/>
Kimberly A. Williams		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature  Date August 10, 2000

Printed Name and Title Sarah J. Walsh, Director, Federal Government Relations

Registrant Name Glaxo Wellcome Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TRD (one per page)

16. Specific lobbying issues

S. 2464 Prescription Drug Fairness Act

S. 2466 A bill to require USTR to enter negotiations to eliminate price controls

17. House(s) of Congress and Federal agencies contacted  Check if None

US Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	Nov
Janie Kinney		<input type="checkbox"/>
Sara Froelich		<input type="checkbox"/>
Sarah J. Walsh		<input type="checkbox"/>
William Schuyler		<input type="checkbox"/>
Elizabeth Beavin		<input type="checkbox"/>
Kimberly Williams		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature  Date August 10, 2000

Printed Name and Title Sarah J. Walsh, Director, Federal Government Relations

Registrant Name Glaxo Wellcome Client Name Self

**Information Update Page - Complete ONLY where registration information has changed.**

20. Client new address

21. Client new principal place of business (if different from line 20)

City \_\_\_\_\_ State/Zip (or Country) \_\_\_\_\_

22. New general description of client's business or activities

**LOBBYIST UPDATE**

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

**ISSUE UPDATE**

24. General lobbying issues previously reported that no longer pertain  
TAX

**AFFILIATED ORGANIZATIONS**

25. Add the following affiliated organization(s)

Name	Address	Principal Place of Business (city and state or country)

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

**FOREIGN ENTITIES**

27. Add the following foreign entities

Name	Address	Principal place of business (city and state or country)	Amount of contribution for lobbying activities	Ownership percentage in client

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

Signature  Date August 10, 2000

Printed Name and Title Sarah J. Walsh, Director, Federal Government Relations